Vanguard Group
TRDA icon

Vanguard Group’s Entrada Therapeutics TRDA Stock Holding History

Vanguard Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$16.8M Buy
1,632,460
+28,235
+2% +$238K ﹤0.01% 2703
2025
Q3 		$9.3M Sell
1,604,225
-635
-0% -$3.71K ﹤0.01% 3018
2025
Q2 		$10.8M Buy
1,604,860
+29,266
+2% +$235K ﹤0.01% 2866
2025
Q1 		$14.2M Buy
1,575,594
+111,357
+8% +$1.39M ﹤0.01% 2659
2024
Q4 		$25.3M Buy
1,464,237
+241,052
+20% +$4.37M ﹤0.01% 2476
2024
Q3 		$19.5M Buy
1,223,185
+93,562
+8% +$1.47M ﹤0.01% 2598
2024
Q2 		$16.1M Buy
1,129,623
+50,715
+5% +$721K ﹤0.01% 2668
2024
Q1 		$15.3M Buy
1,078,908
+13,742
+1% +$194K ﹤0.01% 2725
2023
Q4 		$16.1M Buy
1,065,166
+44,849
+4% +$664K ﹤0.01% 2693
2023
Q3 		$16.1M Buy
1,020,317
+10,568
+1% +$166K ﹤0.01% 2638
2023
Q2 		$15.3M Buy
1,009,749
+81,084
+9% +$1.12M ﹤0.01% 2713
2023
Q1 		$13.5M Buy
928,665
+8,412
+0.9% +$112K ﹤0.01% 2783
2022
Q4 		$12.4M Buy
920,253
+50,106
+6% +$878K ﹤0.01% 2851
2022
Q3 		$13.7M Buy
870,147
+107,783
+14% +$1.37M ﹤0.01% 2801
2022
Q2 		$9.29M Buy
762,364
+331,960
+77% +$2.52M ﹤0.01% 3031
2022
Q1 		$4.04M Buy
430,404
+5,452
+1% +$58.5K ﹤0.01% 3628
2021
Q4 		$7.27M Buy
+424,952
New +$10.3M ﹤0.01% 3406

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group's TRDA Position: Q4 2025 in Review

Vanguard Group increased its Entrada Therapeutics (TRDA) stake by 1.8% in Q4 2025, buying an estimated $238K and bringing the position to 1,632,460 shares worth $16.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2703.

Vanguard Group first reported a position in TRDA in Q4 2021 and has held it in 17 quarters since. The position peaked at $25.3M in Q4 2024. 114 funds tracked by Wall St. Rank hold TRDA as of Q4 2025.

  • Vanguard Group held 1,632,460 shares of Entrada Therapeutics worth $16.8M as of Q4 2025.
  • Vanguard Group bought 28,235 Entrada Therapeutics shares in Q4 2025, an estimated $238K.
  • Entrada Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2703 holding.
  • Vanguard Group first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • Vanguard Group's Entrada Therapeutics position peaked at $25.3M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.